An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis

NCT07665723 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Active Ulcerative Colitis

Interventions

DRUG: Afimkibart
DRUG: Caffeine
DRUG: Warfarin
DRUG: Omeprazole
DRUG: Dextromethorphan
DRUG: Midazolam
OTHER: Vitamin K

Sponsor

Hoffmann-La Roche